« Back to Record
Loibl, S., Von Minckwitz, G., Schneeweiss, A., Paepke, S., Lehmann, A., Rezai, M., Zahm, D. D., Sinn, P., Khandan, F., Eidtmann, H., Dohnal, K., Heinrichs, C., Huober, J., Pfitzner, B. B., Fasching, P. A., Andre, F., Lindner, J. J., Sotiriou, C., Dykgers, A., Guo, S., Gade, S., Nekljudova, V., Loi, S., Untch, M., & Denkert, C. (2014). PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. Journal of clinical oncology, 32(29), 3212-3220. doi:10.1200/JCO.2014.55.7876
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/186695



